Uric acid is the final product of purine metabolism in humans — produced from the breakdown of adenine and guanine nucleotides from DNA and RNA turnover, and from dietary purines. Elevated uric acid (hyperuricemia) causes gout, but its longevity relevance extends far beyond joint inflammation: it is independently associated with hypertension, insulin resistance, kidney disease, and cardiovascular mortality through mechanisms that go well beyond urate crystal deposition.
Uric acid receives attention in clinical medicine primarily when it produces gout — the painful acute arthritis caused by monosodium urate crystal deposition in joints when serum uric acid exceeds approximately 6.8 mg/dL (the solubility threshold). But the longevity-relevant story of uric acid extends well beyond gout. Hyperuricemia is an early metabolic derangement that precedes hypertension, insulin resistance, and cardiovascular disease by years to decades — not merely as a biomarker of metabolic dysfunction, but through causal mechanisms that include endothelial dysfunction, renin-angiotensin system activation, and mitochondrial oxidative stress.1
Purines — adenine and guanine — are the nitrogen-containing bases of DNA and RNA. Their catabolism produces hypoxanthine and xanthine, which are converted to uric acid by the enzyme xanthine oxidase. Humans and great apes lack the enzyme uricase (urate oxidase) that converts uric acid to the more soluble allantoin — a loss-of-function mutation that occurred approximately 15 million years ago and produces much higher circulating uric acid than is found in most mammals. This evolutionary quirk makes humans uniquely susceptible to hyperuricemia and gout.2
Uric acid is cleared primarily by the kidneys (approximately 70 percent) and gut (approximately 30 percent). Renal urate handling involves glomerular filtration followed by proximal tubule reabsorption (via URAT1 transporter) and secretion (via ABCG2). Most hyperuricemia in adults is caused by underexcretion (90 percent of cases) rather than overproduction — the result of reduced renal urate clearance driven by insulin resistance (insulin reduces renal urate excretion), dehydration, medications (particularly thiazide diuretics and low-dose aspirin), and genetic variation in urate transporters.
Fructose metabolism is uniquely linked to uric acid production through a mechanism distinct from glucose or fat metabolism. When fructose is phosphorylated by fructokinase in the liver, it rapidly depletes hepatocyte ATP — because fructokinase lacks the feedback inhibition that regulates hexokinase (the glucose phosphorylating enzyme). ATP depletion produces AMP, which is deaminated to IMP and then degraded to hypoxanthine and ultimately uric acid. This ATP-depleting pathway is activated by every high-dose fructose exposure — explaining why sugar-sweetened beverages (which deliver large fructose loads rapidly) consistently elevate uric acid in intervention trials. A single 600 mL sugar-sweetened beverage can transiently raise serum uric acid by 1-2 mg/dL.3
Uric acid may be a cause of hypertension rather than merely a consequence — a causal mechanism supported by multiple lines of evidence. In animal models, induction of hyperuricemia produces hypertension that reverses when uric acid is lowered. In pediatric studies, hyperuricemia in adolescents precedes hypertension development. Mendelian randomization analyses using genetic variants in urate transporter genes as instruments find that genetically predicted higher uric acid causally elevates blood pressure. The proposed mechanism: uric acid stimulates renin-angiotensin system activation, impairs endothelial nitric oxide synthesis, and promotes afferent arteriolar vasoconstriction in the kidney — all of which raise blood pressure.4
For most adults with elevated uric acid below the gout threshold (6.8 mg/dL), dietary and lifestyle interventions are the primary approach. The most impactful: Eliminate sugar-sweetened beverages (the most potent dietary uric acid driver), reduce alcohol (particularly beer and spirits), increase hydration (dehydration concentrates urate and reduces renal excretion), achieve and maintain healthy weight (insulin resistance is the dominant driver of underexcretion), reduce dietary purines from red meat and shellfish (though this has modest effects compared to eliminating SSBs). For uric acid consistently above 7-8 mg/dL with metabolic risk factors, pharmaceutical urate-lowering therapy (allopurinol, febuxostat) may be appropriate in discussion with a physician.5
